Synopsis of key findings
This clinical trial demonstrated that betahistine is no more effective
than a placebo to treat primary tinnitus. The THI score improvement was
minimal and without significant difference between study groups.
Additionally, the secondary endpoint, covariate adjustment, and
per-protocol analysis provided similar results and side effects were
without difference across both groups.